Purpose of review
The current review highlights recent advances in treatment of chronic hepatitis C virus
infection using new classes of agents, direct-acting antivirals (DAAs), with a focus on the evidence for their use in the setting of chronic kidney disease
(CKD) stages 4–5, hemodialysis, and kidney transplantation.
DAA agents target-specific proteins involved in the hepatitis C virus
life cycle and interrupt viral replication. Sustained virologic response
, a marker of viral eradication, occurs in more than 90% of patients treated with DAA agents in the general population. Emerging data demonstrate similar sustained virologic response
rates for specific DAA-based regimens in patients with CKD stages 4–5, hemodialysis patients, and kidney-transplant recipients.
High sustained virologic response
rates are seen with DAA agents in CKD populations. A thoughtful approach to the timing of treatment is required to facilitate timely access to kidney transplantation.